

(Sharecast News) - Speciality pharmaceuticals company Diurnal reported 6% growth in first-half total revenue in its interim results on Tuesday, to ...


UPDATE: Diurnal Loss Widens In First Half; Signs Chronocort Deal


Diurnal Reports Widened Loss In First Half Despite Revenue Growth


UK Earnings, Trading Statements Calendar - Next 7 Days


Diurnal Inks Licence Agreement For Alkindi With Citrine Medicine


UK TRADING UPDATE SUMMARY: DWF Sets Up New Global Operating Structure


IN BRIEF: Diurnal Pleased With Alkindi Sales In First Half


IN BRIEF: Diurnal Inks Turkey Distribution Deal For Alkindi, Chronocort